Tools for Practice Outils pour la pratique


#358: Any berry good solutions to preventing UTIs: Cranberries?


CLINICAL QUESTION
QUESTION CLINIQUE
Do cranberry products prevent recurrent urinary tract infections (UTIs)?


BOTTOM LINE
RÉSULTAT FINAL
Potential benefits of cranberry products for UTI prevention are at high risk-of-bias from potential publication bias, small studies, and unblinding. If biases disregarded, cranberry products might reduce the proportion of women with recurrent UTIs from 24% to 18% over ≤1 year. Results are inconsistent between patient populations; example children with recurrent UTIs may benefit but not institutionalized elderly or pregnant woman.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • 5 systematic reviews [7-50 randomized control trials (RCTs), 1498-8857 patients].1-5 UTI definition varied: Symptoms, bacteriuria, or both. Results statistically different unless stated.
  • Most recent/largest systematic review (50 RCTs, 8857 patients).1 “People-at-risk” subgroups included women (generally ≥2 UTIs/year) or children (1-18 years with ≥1 past UTI), adults with pelvic radiation/surgery/transplant or neuromuscular dysfunction, institutionalized elderly, and pregnant women. Any cranberry product versus placebo or no-treatment.  ≥1 UTI at 1-12 months (reporting subgroups, due to inconsistent results):
    • Women (8 RCTs, 1555 patients): 18% versus 24% placebo, Number Needed to Treat (NNT)=17.
    • Children (5 RCTs, 504 patients): 16% versus 34% placebo, NNT=6.
    • Adults following pelvic radiation/surgery/transplant (6 RCTs, 1434 patients): 11% versus 23% placebo, NNT=9.
    • Institutionalized adults, pregnant women, or neuromuscular dysfunction: No statistical difference.
  • Other systematic reviews: Women with recurrent UTIs2,3 and any “people-at-risk”4,5 report benefits.
  • Adverse events: No difference.1
  • Limitations:
    • Publication bias:5 UTI prevention Risk Ratio (RR)=0.68 [Confidence Interval (CI):0.57-0.80] worsens when adjusted for missing studies [RR=0.83 (CI:0.70-1.00)].
    • Systematic reviews1-5 did no analysis by quality. PEER performed quality analysis for study size and placebo-controlled (in women with recurrent UTI).1
      • Smaller RCTs RR=0.47 (CI:0.33-0.68) versus large RCTs RR=0.97 (CI:0.77-1.22), statistically different.
      • No-placebo (unblinded) RCTs RR=0.39 (CI:0.21-0.74) versus placebo RR=0.83 (CI:0.62-1.10), statistically different.

CONTEXT
CONTEXTE
  • Proanthocyanidin (proposed active ingredient) studied dose varied 2.8-118 mg.
  • For women, typical cranberry intervention was juice (1/2-3 cups/day) or capsule (500mg/day).1
  • Cranberry juice versus capsules (1 RCT, 100 patients):6 No statistical difference.
  • Daily antibiotics reduce recurrence to 12% over 6-12 months versus 66% with placebo.7
  • Guidelines support antibiotic prophylaxis with conditional recommendation for cranberry.8
  • Costs:9 Juice/cup: ~$0.60; 110 calories (low-calorie: 10 calories).
  • Capsules: ~$0.15-0.63/capsule (doses vary).


Marlene Fuhrmann February 1, 2024

very interesting–such a common self treatment among patients

Ralph Suke March 30, 2024

Seems to confer some small benefit.


Latest Tools for Practice
Derniers outils pour la pratique

#368 Sodium Restriction in Heart Failure: Beneficial or pouring salt in the wound?

Does sodium restriction improve outcomes in patients with chronic heart failure?
Read Lire 0.25 credits available Crédits disponibles

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Jennifer Young MD CCFP-EM
  • G. Michael Allan MD CCFP
  • Betsy Thomas BSc. Pharm

1. Williams G, Hahn D, Stephens JH, et al. Cochrane Database Syst Rev. 2023; 4(4):CD001321.

2. Valente J, Pendry BA, Galante E. J Herbal Med. 2022;36; 100602.

3. Fu Z, Liska D, Talan D, et al. J Nutr. 2017; 147(12):2282-2288.

4. Xia JY, Yang C, Xu DF, et al. PLoS One. 2021; 16(9):e0256992.

5. Luís Â, Domingues F, Pereira L. J Urol. 2017; 198(3):614-621.

6. Stothers L. Can. J Urol. 2002; 9(3):1558-62.

7. Finley C, Falk J, Korownyk T. Tools for Practice #322 (online publication), College of Family Physicians of Canada, 2022; Sept. 6. Available at: https://cfpclearn.ca/tfp322/ Accessed on: November 23, 2023.

8. Anger J, Lee U, Ackerman AL, et al. J Urol. 2019; 202(2):282-289.

9. Real Canadian Superstore website. Available at: https://www.realcanadiansuperstore.ca. Accessed on October 25, 2023.

Authors have no conflicts of interest to declare.